B virus infection

Gripon P, Cannie I, Urban S (2005). EfScient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein. J Virol 79 1613-1622 Harris RS, Liddament MT (2004) Retroviral restriction by APOBEC proteins. Nat Rev Immunol 4 868-877... [Pg.22]

Petersen J, Dandri M, Mier W, Lfltgehetmann M, Volz T, von Weizsacker F, Haberkom U, Fischer L, Pollok JM, Erbes B, Seitz S, Urban S (2008) Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein, Nat Biotechnol 26 335-341 PorniUos O, Garrus JE, Sundquist WI (2002) Mechanisms of enveloped RNA virus budding. Trends CeU Biol 12 569-579... [Pg.24]

Abstract In 2007, the world celebrated the 50th anniversary of the discovery of interferon (IFN) by Isaacs and Lindemnann. Subsequently, the IFN-a gene was cloned, fully sequenced and IFN-a was produced in recombinant form. Recombinant IFN-a is now used as the basis for treatment of chronic hepatitis C virus infection and can also be used to treat certain forms of chronic hepatitis B virus infections. IFNs have also been used in other viral infections, although with less success. The antiviral mechanisms of IFNs are reviewed in this chapter as well as the utility of IFNs in the treatment of persistent viral infections. [Pg.204]

Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER, Tobias H, Wright TL (2006) A treatment algorithm for the management of chronic hepatitis B virus infection in the United States an update. Clin Gastroenterol Hepatol 4 936-962 Kim KI, Sasase N, Taniguchi M, Mita K, Kinoshita K, Togitani T, Shikata M, Kimura N, Izawa S, Ohtani A, Nakao K, Muramoto Y, Kim SR, Nabeshima S, Ishii F, Tanaka K, Hayashi Y (2005) Interferon-beta induction/interferon-alpha2b plus ribavirin therapy in patients with chronic hepatitis C. Int J Clin Pharmacol Res 25 71-76... [Pg.236]

Nowak MA, Bonhoeffer S, HiU AM, Boehme R, Thomas HC, McDade H (1996) Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci USA 93 4398 402... [Pg.294]

Lok AS, McMahon BJ (2007) Chronic hepatitis B. Hepatology 45(2) 507-539 Manesis EK, Papatheodoridis GV, Sevastianos V, Cholongitas E, Papaioannou C, Hadziyannis SJ (2003) Significance of hepatitis B viremia levels determined by a quantitative polymerase chain reaction assay in patients with hepatitis B e antigen-negative chronic hepatitis B virus infection. Am J Gastroenterol 98(10) 2261-2267... [Pg.344]

From Centers for Disease Control and Prevention. A Comprehensive Immunization Strategy to Eliminate Transmission of Hepatitis B Virus Infection in the United States. Recommendations of the Advisory Committee on Immunization Practices (ACIP) Part 1 Immunization of Infants, Children, and Adolescents. http //www.cdc.gov/mmwr/preview/mmwrhtml/rr5416a1. htm s cid=rr5416a1 e. [Pg.354]

Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States an update. Clin Gastroenterol Hepatol 2006 4 936-962. [Pg.359]

Heijtink RA, De Wilde GA, Kruining J, Berk L, Balzarini J, De Clercq E, Holy A, Schalm SW. Antiviral activity of 9-(2-phosphonylmethoxyethyl) adenine (PMEA) on human and duck hepatitis B virus infection. Antiviral Res 1993 21 141-153. [Pg.335]

HIV is present in peripheral blood mononuclear cells, the major source of transmitted virus. Titers, however, are quite low, about 10,000 infectious doses per ml of blood, so that the blood is less infectious than in hepatitis B virus infections. The amount present tends to fall after seroconversion and rises again during development of AIDS-related complex and AIDS. Smaller amounts of virus are also present in semen and saliva, and probably even smaller amounts in colostrum, the human cervix, and tears. Infection is reported in CD4 positive submucosal cells in the rectum and large bowel and could be a route of entry in homosexuals. [Pg.201]

It is used for active immunization against hepatitis B virus infection. [Pg.439]

The same name is also being used for some vaccines that differ in potency. As shown in Table 1.4, the two approved vaccines against hepatitis B, Recombivax HB and Engerix-B, both known as Hepatitis B Vaccine (Recombinant), when used as directed, are therapeutically equivalent in terms of their ability to induce antibodies that protect vaccinated individuals from hepatitis B virus infection. However, the dose and volume required to produce a satisfactory immune response are different for each product and for each age group. [Pg.10]

Similarly, concern about minute amounts of contaminants co-purified with human growth hormone extracted from brain tissues, which could lead to the development of Jacob-Kreutzfeld syndrome, inevitably resulted in the development of recombinant human growth hormone. Inactivated hepatitis B particles isolated from hepatitis B-positive patients were originally used to prevent hepatitis B virus infection, but a small fraction of individuals became infected through vaccination. When the hepatitis B surface antigen was... [Pg.30]

Greenberg, H.B., R.B. Pollard, L.I. Lutwick, PB. Gregory, W.S. Robinson, and T.C. Merigan, Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis. New Engl J Med, 1976. 295 517-22. [Pg.183]

Brook, M.G., P. Karayiannis, and H.C. Thomas, Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy A statistical analysis of predictive factors. Hepatology, 1989. 10 761-63. [Pg.184]

Franzece O, Kennedy PTF, Gehring AJ, Gotto GM., et al. 2005. Modulation of the CD8+ T cell response by CD4+CD25+ regulatory T cells in patients with Hepatitis B virus infection. J Virol. 79 3322-3328. [Pg.224]

R. G. Gish and E. B. Keeffe, Recent developments in the treatment of chronic hepatitis B virus infection, Exp. Opin. Invest. Drugs 4 95-115 (1995). [Pg.236]

F6. Pemice, W., Sosomann, C., Luben, G., Seiler, F, R., and Sedlacek, H. H., Antigen-specific detection of HBsAg-containing immune complexes in the course of hepatitis B virus infection. Clin. Exp. Immunol. 37, 376-380 (1979). [Pg.53]

A)-Peniciclovir phosphates, (I), prepared by Vere Hodge (1) and N4-acylcytosine-1,3-dioxolane nucleoside derivatives, (II), prepared by Du (2) and Watanabe (3) were effective in the treatment of both HIV-1 and hepatitis B virus infections in mammals. [Pg.17]

Lee WM. Hepatitis B virus infection. N Engl J Med 1997 336 1733-1745. Buendia MA. Hepatitis B viruses and carcinogenesis. Biomed Pharmacother 1998 52 34-43. [Pg.72]

Liaw YF, Chen YC, Sheen I, et al. Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection. Gastroenterology 2004 126 1024-1029. [Pg.72]

Peers F, Bosch X, Kaldor J, Linsell A, Pluijiman M Aflatoxin exposure, hepatitis B virus infection and liver cancer in Swaziland. Int J Cancer 1987 39 545-553. [Pg.200]

An example of the use of a terpene as a chiral auxiliary is provided by the synthesis of the anti-viral reverse transcriptase inhibitor Lamivudine (148). The nucleoside analog is marketed by Biochem Pharma (now Shire Pharmaceuticals) and Glaxo Wellcome (now GlaxoSmithKline) for the treatment of HIV and hepatitis B virus infection. In the... [Pg.812]

New England Journal of Medicine 345 41-52 Lee W M 1997 Hepatitis B virus infection. New England Journal of Medicine 337 1733-1745 Martin P-Y et al 1998 Nitric oxide as a mediator of haemodynamic abnormalities and sodium and water retention in cirrhosis. New England Journal of Medicine 339 533-541... [Pg.659]

Fig. 5.7 Ground-glass hepatocytes (see arrows) in chronic hepatitis B virus infection (s. figs. 22.7, 22.8)...

Hutin, Y.XF., Goldstein, S.T., Varma, XK., Odair, XB., Mast, E.E., Shapiro, C.N., Alter, M.X An outbreak of hospital-acquired hepatitis B virus infection among patients receiving chronic hemodialysis. Inf. Contr. Hosp. Epid. 1999 20 731 -735... [Pg.454]

Inman, R.D. Rheumatic manifestations of hepatitis B virus infection. Semin. Arthr. Rheum. 1982 11 406 - 420... [Pg.454]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...